Compensation is always tricky to determine, both as a professional and for organisations. Across all markets, ...Read more
How is QIAGEN helping to reduce the growing burden of TB in APAC? QIAGEN promotes TB prevention (Test and Tre...Read more
What will be your latest innovations in the healthcare and pharma industry? Freudenberg is a global t...Read more
Catalent has announced the expansion of its primary packaging capabilities at its clinical supply facilit...Read more
Merck has announced that its Life Science business sector has doubled its high-potent active pharmaceutical in...Read more
Keeping Pace with MUTATING VIRUSES
A surge in the pandemic has forced the pharma industry to deliver a wide-spectrum vaccine to fight mutation-prone SARS-CoV-2, pledging to prevent future outbreaks. WHO states that the most extensive vaccination campaign in history is providing prophylactic results by delivering more than 12 billion doses of the COVID-19 vaccine, protecting 60 per cent of the global population as of June 2022. Now the next-generation COVID-19 vaccines are countering the challenge of enhancing the immune response to tackle the emerging COVID-19 variants. It is therefore imperative to remain vigilant and upgrade vaccine candidates to emerging virus sublineages. In order to gain a competitive position in the market, vaccine manufacturers are investing in advanced platform technologies. Let’s take a closer look at some of these leading vaccines approved in APAC as broad spectrum virucide inhibitors.
For Feedback Email Us: firstname.lastname@example.org